Stocktoria
Anika Therapeutics, Inc. ANIK
Anika Therapeutics, Inc. (ANIK) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $112.8M at a -9.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.91 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.428 |
| Retained earnings / assets | 0.319 |
| EBIT / assets | -0.058 |
| Equity / liabilities | 3.065 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ANIK | Anika Therapeutics, Inc. | 5/9 | 6.68 | — | -5.9% |
| OSUR | ORASURE TECHNOLOGIES INC | 2/9 | 6.76 | — | -38.1% |
| BBNX | Beta Bionics, Inc. | 4/9 | 6.94 | — | +53.9% |
| NPCE | NeuroPace Inc | 5/9 | -13.13 | — | +25.1% |
| KMTS | KESTRA MEDICAL TECHNOLOGIES, LTD. | 5/9 | -0.94 | — | +59% |
| XTNT | Xtant Medical Holdings, Inc. | 8/9 | -3.66 | 12.7 | +14.2% |
| LUNG | Pulmonx Corp | 3/9 | -11.04 | — | +8% |
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
FAQ
Is ANIK financially healthy?
Anika Therapeutics, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does ANIK pay a dividend?
No, Anika Therapeutics, Inc. does not currently pay a dividend.
How profitable is ANIK?
In FY2025, Anika Therapeutics, Inc. had a net margin of -9.6% and a return on equity of -7.6%.
Is ANIK overvalued or undervalued?
Anika Therapeutics, Inc. trades at about 78.7× trailing earnings — above its 10-year norm (10-year range 13.0×–113.6×, median 23.5×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for ANIK?
The average Wall-Street price target for Anika Therapeutics, Inc. is $17.50, about 20.6% below the recent price, from 2 analysts.
Is ANIK a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Anika Therapeutics, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.